We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Taiho Pharmaceutical

News List

Taiho signs drug licensing deal with Lung Therapeutics in Japan pharmaceutical-technology
November 13, 2020
Taiho Pharmaceutical has entered an exclusive licence agreement with Lung Therapeutics for the latter’s investigational recombinant human single-chain urokinase plasminogen activator, LTI-01, in Japan.
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology pharmaceutical-technology
February 20, 2019
Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for lung cancer to Cullinan Oncology....
Japan's Taiho Pharmaceutical Announces Expansion into Canada americanpharmaceuticalreview
March 09, 2017
Taiho Pharmaceutical Co has established its subsidiary Taiho Pharma Canada, Inc. inOakville, Ontario. The Canadian operations will be managed by Taiho Oncology, Inc., the U.S. R&D and commercial operations of the Taiho Group, based in Princeton, N.J.